Figure 3.

Pretargeted doxorubicin delivery in vitro. a) Flowchart depicting TZ@SWCNTs pretargeting and subsequent tDOX treatment. b) Cytotoxicity of DOX, prodrug tDOX, and pretargeted strategy on MDA‐MB‐231 and SK‐BR‐3 breast cancer cells (n=3; error bars represent the STD). Blue and yellow lines indicate cells treated with DOX or tDOX of different concentrations for 72 h. For orange lines, cells were pretreated with TZ@SWCNTs (20 μm) for 6 h before replacing the media to complete medium with various concentration of tDOX for another 72 h. c) Calculated EC₅₀ (half‐maximal effective concentration) values for DOX, prodrug tDOX, and pretargeted strategy against MDA‐MB‐231 and SK‐BR‐3 breast cancer cells. d) Cytotoxicity of the vehicle (TZ@SWCNTs, black bar) and pretargeted strategy (grey bar) on MDA‐MB‐231 and SK‐BR‐3 breast cancer cells (n=3; error bars represent the STD).